| Literature DB >> 15528692 |
Man-Fung Yuen1, Scott K Fung, Yasuhito Tanaka, Takanobu Kato, Masashi Mizokami, John Chi-Hang Yuen, Danny Ka-Ho Wong, He-Jun Yuan, Siu-Man Sum, Annie On-On Chan, Benjamin Chun-Yu Wong, Ching-Lung Lai.
Abstract
The aims of this study were to compare chronic hepatitis B (CHB) patients with genotypes B and C for the probability of HBeAg seroconversion, hepatitis activity, and viral replication before and after HBeAg seroconversion and to compare the prevalence of core promoter and precore mutations. A total of 180 asymptomatic Chinese patients with CHB were monitored for a median of 53.8 months, and 38 patients with cirrhosis-related complications were studied. Hepatitis B virus (HBV) DNA levels were measured in 16 patients with HBeAg seroconversion at 3 months before, during, and 3 months after HBeAg seroconversion and in all patients at the last follow-up. Hepatitis B genotypes and core promoter and precore mutations were determined. Compared to patients with genotype C (n = 109), patients with subtype Ba (n = 69) had a higher rate of anti-HBe positivity on presentation (P = 0.05). HBeAg-positive patients with subtype Ba had a higher cumulative rate of HBeAg seroconversion than patients with genotype C (P = 0.02). However, there were no differences between the two groups with regard to the median HBV DNA levels before, during, and after HBeAg seroconversion; the probability of having persistently normal or elevated aminotransferase levels; and the median HBV DNA levels and liver biochemistry at the last follow-up. There was no difference in the prevalence of genotypes and core promoter and precore mutations between patients with and without cirrhosis-related complications. Though patients with subtype Ba had earlier HBeAg seroconversion, the liver biochemistry, HBV DNA levels in different phases of the disease, and the probability of development of cirrhosis-related complications were the same with genotypes Ba and C.Entities:
Mesh:
Substances:
Year: 2004 PMID: 15528692 PMCID: PMC525264 DOI: 10.1128/JCM.42.11.5036-5040.2004
Source DB: PubMed Journal: J Clin Microbiol ISSN: 0095-1137 Impact factor: 5.948